NOVEL EUROPEAN PRRSV STRAIN

• US 20170065709A1
• Filed: 11/22/2016
• Published: 03/09/2017
• Est. Priority Date: 02/17/2011
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: BURGARD, Kim, KROLL, Jeremy, LAYTON, Sarah M., OHLINGER, Volker, ORVEILLON, Francois-Xavier, PESCH, Stefan, PIONTKOWSKI, Michael Dennis, ROOF, Michael B., UTLEY, Philip, VAUGHN, Eric Martin
• Granted Patent: US 10,039,821 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2770/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/10064 by serial passage
• CPC Class Codes: C12N 2770/10071 Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines.

Claims

1. A Porcine Reproductive and Respiratory Syndrome (PRRS) virus having an RNA nucleotide sequence that is at least 95% homologous with the DNA sequence set forth in either SEQ ID NO:

1 or SEQ ID NO;

10.

2. A PRRS virus according to claim 1, wherein said PRRS virus has an RNA nucleotide sequence that corresponds to the DNA sequence set forth in either SEQ ID NO:

1 or SEQ ID NO;

10.

3. A vaccine for the production of pigs against a PRRS virus infection, comprising a PRRS virus according to claim 1 and a pharmaceutically acceptable carrier, wherein said PRRS virus has an RNA nucleotide sequence that corresponds to the DNA sequence set forth in SEQ ID NO:

1 or is an attenuated PRRS virus that that has an RNA nucleotide sequence that is at least 95% homologous with the DNA sequence set forth in SEQ ID NO;

1.

4. The vaccine according to claim 3, which further comprises one or more non-PRRS virus attenuated or inactivated pathogens or antigenic material thereof.

5. The vaccine according to claim 4, wherein said non-PRRS virus pathogens are selected from Pseudorabies virus, Porcine Influenza virus, Porcine Parvovirus, Transmissible gastroenteritis virus, Escherichia coli, Erysipelo rhusiopathiae, Bordetella bronchiseptica, Salmonella cholerasuis, Haemophilus parasuis, Pasterella multocida, Streptococcus suis, Mycoplasma hypopneumoniae and Actinobacillus pleuopneumoniae.